Literature DB >> 26695691

Accuracy of screening instruments for detection of neuropsychiatric syndromes in Parkinson's disease.

Pablo Martinez-Martin1, Albert F G Leentjens2, Jesus de Pedro-Cuesta1, Kallol Ray Chaudhuri3,4, Anette E Schrag5, Daniel Weintraub6,7.   

Abstract

Parkinson's disease includes neuropsychiatric manifestations, such as depression, anxiety, apathy, psychosis, and impulse control disorders, which often are unreported by patients and caregivers or undetected by doctors. Given their substantial impact on patients and caregivers as well as the existence of effective therapies for some of these disorders, screening for neuropsychiatric symptoms is important. Instruments for screening have a particular methodology for validation, and their performance is expressed in terms of accuracy compared with formal diagnostic criteria. The present study reviews the attributes of the screening instruments applied for detection of the aforementioned major neuropsychiatric symptoms in Parkinson's disease. A quasi-systematic review (including predefined selection criteria, but not evaluating the quality of the reviewed studies) was carried out on the basis of previous systematic reviews (commissioned by the American Academy of Neurology and the Movement Disorder Society) and made current by conducting a literature search (2005-2014). For depression, 11 scales and questionnaires were shown to be valid for Parkinson's disease screening. The recently developed Parkinson Anxiety Scale and the Geriatric Anxiety Inventory demonstrate satisfactory properties as screening instruments for anxiety, and the Lille Apathy Rating Scale for detection of apathy. No scale adequately screens for psychosis, so a specific psychosis instrument should be developed. The Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease (Questionnaire and Rating Scale) are valid for comprehensive screening of impulse control disorders, and the Parkinson's Disease-Sexual Addiction Screening Test for hypersexuality specifically.
© 2015 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Parkinson's disease; accuracy; instruments; neuropsychiatric symptoms; screening

Mesh:

Year:  2015        PMID: 26695691     DOI: 10.1002/mds.26522

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  19 in total

1.  Brain structural and functional signatures of impulsive-compulsive behaviours in Parkinson's disease.

Authors:  F Imperiale; F Agosta; E Canu; V Markovic; A Inuggi; M Jecmenica-Lukic; A Tomic; M Copetti; S Basaia; V S Kostic; M Filippi
Journal:  Mol Psychiatry       Date:  2017-03-07       Impact factor: 15.992

Review 2.  Cognitive and behavioral disorders in Parkinson's disease: an update. II: behavioral disorders.

Authors:  Luigi Trojano; Costanza Papagno
Journal:  Neurol Sci       Date:  2017-10-16       Impact factor: 3.307

3.  The movement disorder society nonmotor rating scale: Initial validation study.

Authors:  K Ray Chaudhuri; Anette Schrag; Daniel Weintraub; Alexandra Rizos; Carmen Rodriguez-Blazquez; Eugenia Mamikonyan; Pablo Martinez-Martin
Journal:  Mov Disord       Date:  2019-09-30       Impact factor: 10.338

Review 4.  Neuropsychiatric aspects of Parkinson's disease.

Authors:  Anna Nagy; Anette Schrag
Journal:  J Neural Transm (Vienna)       Date:  2019-05-29       Impact factor: 3.575

Review 5.  Depression in Patients with Parkinson's Disease: Current Understanding of its Neurobiology and Implications for Treatment.

Authors:  Stéphane Prange; Hélène Klinger; Chloé Laurencin; Teodor Danaila; Stéphane Thobois
Journal:  Drugs Aging       Date:  2022-06-16       Impact factor: 4.271

Review 6.  Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.

Authors:  Anna Chang; Susan H Fox
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

7.  The Prevalence and Determinants of Neuropsychiatric Symptoms in Late-Stage Parkinsonism.

Authors:  Adrianus L A J Hommel; Marjan J Meinders; Stefan Lorenzl; Richard Dodel; Miguel Coelho; Joaquim J Ferreira; Brice Laurens; Umberto Spampinato; Wassilios Meissner; Kristina Rosqvist; Jonathan Timpka; Per Odin; Michael Wittenberg; Bas R Bloem PhD; Raymond T Koopmans; Anette Schrag
Journal:  Mov Disord Clin Pract       Date:  2020-05-21

8.  Multidimensional Apathy: The Utility of the Dimensional Apathy Scale in Huntington's Disease.

Authors:  Kelly J Atkins; Sophie C Andrews; Trevor T-J Chong; Julie C Stout
Journal:  Mov Disord Clin Pract       Date:  2021-02-12

Review 9.  The neuropsychiatry of Parkinson's disease: advances and challenges.

Authors:  Daniel Weintraub; Dag Aarsland; Kallol Ray Chaudhuri; Roseanne D Dobkin; Albert Fg Leentjens; Mayela Rodriguez-Violante; Anette Schrag
Journal:  Lancet Neurol       Date:  2022-01       Impact factor: 44.182

10.  Preliminary Findings on Proline-Rich Protein 14 as a Diagnostic Biomarker for Parkinson's Disease.

Authors:  Tao Jin; Xuling Tan; Xiaoliu Shi; Lingling Lv; Xinke Peng; Hainan Zhang; Beisha Tang; Chunyu Wang; Mei Yang
Journal:  Neuromolecular Med       Date:  2020-10-01       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.